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INTRODUCTION
Autoimmune diseases that attack the peripheral
nervous system are rare and difficult to precisely
diagnose. Current diagnostic techniques rely heavily
on patient symptomatology which proves problematic
considering the varying presentations and the
interchangeability of symptoms among many
peripheral neuropathies. Little is understood about the
precise mechanism of pathogenesis which makes
obtaining a biomarker challenging, but the presence of
autoantibodies that target myelin proteins suggest a
humoral component in the degeneration of the myelin
sheath. In previous studies, antiganglioside IgG and
IgM antibodies that attack myelin have been reported
in up to 60% of cases of Guillain-Barre syndrome (GBS)
and 50% of cases of multifocal motor neuropathy
(MMN). However, there are fewer cases of
antiganglioside antibodies reported in chronic
inflammatory demyelinating polyneuropathy (CIDP)
with some studies citing antibodies in less than 10% of
cases. This study aims to examine the current
diagnostic criteria and provide insight on
antiganglioside antibodies as possible diagnostic
indicators by examining previously completed studies.
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Primary article selection began with keyword
searches in PubMed and Google Scholar
Keywords: Antiganglioside antibodies in CIDP, GBS,
and MMN
Selected studies from reference lists in primary
search
Defined inclusion criteria:
• Patient sera
• IgG or IgM antiganglioside antibodies
• Comparative study
• Reported total number of participants
• Antibody titer threshold
9 studies met the defined inclusion criteria
5 studies were included in each analysis (1 study
provided a comparison for both analyses)
• Analysis comparing CIDP and GBS
• Analysis comparing CIDP and MMN
The random effects meta-analyses were completed
using the software Review Manager (RevMan)
version 5.4

CONCLUSION

RESULTS

Meta-Analysis Comparing CIDP and GBS:

Figure 1. Forest plot of random effects meta-analysis comparing the presence of either IgG or IgM
antiganglioside antibodies in CIDP and GBS. The IgG or IgM antiganglioside antibodies were not epitope
specific, in that they were not specific to a distinct ganglioside within the myelin. The results revealed
considerable heterogeneity across studies (I2 = 78%). No significant difference was found (P = 0.14) in the
presence of antiganglioside antibodies in CIDP and GBS.

These findings provide some encouragement for the
potential use of antiganglioside antibodies as
diagnostic indicators in combination with previously
established criteria. According to previous studies it is
evident that these antibodies play a role in the
pathogenesis of neuropathies like GBS and MMN.
Their
role
in
complement
fixation
and
neuroinflammation appears to be a significant
contributing factor in the dysfunction of nerve
conduction observed in peripheral neuropathies. This
makes them an ideal target as a biomarker for MMN or
GBS given their implication in pathogenesis. Detection
of elevated antiganglioside antibodies in patient serum
may also prove useful in eliminating CIDP as the
peripheral neuropathy. However, it should be
recognized that these diseases are rare with few
studies investigating this and further research is
needed in disease pathogenesis.

FUTURE DIRECTIONS
•

Meta-Analysis Comparing CIDP and MMN:

•

•

A deeper understanding of disease pathogenesis
may give rise to more reliable biomarkers
Antiganglioside antibodies have been shown to be
useful in treatment indications
• Seropositive patients respond poorly to
IVIg
• Benefit from corticosteroids and plasma
exchange
The lack of precise diagnostic methods and high
incidence of misdiagnoses question the validity of
current populations studies
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